CS Paper Radar

Multi-Agent Retrieval-Augmented Causality Assessment (MARCA) of Individual Case Safety Reports in Pharmacovigilance

Daisy Rae Lopez, Angela Boccia, Maurizio Sessa

cs.CL ·submitted 2026-10-23 20:43 UTC · v1

Abstract

Introduction: Increasing volumes of individual case safety reports (ICSRs) challenge expert-led causality assessment in pharmacovigilance. We developed MARCA (Multi-Agent Retrieval-Augmented Causality Assessment), a four-agent framework for Naranjo-based assessment, and evaluated agreement with human experts and exploratory differences between non-RAG and RAG-labelled scores. Methods: MARCA combined scientific literature retrieval, drug-label assessment, objective-evidence classification, and clinical causality reasoning using Gemini 2.5 Pro and DeepSeek-V3.2. Agent-generated rationales informed human-assisted scoring. A consensus expert reference standard covered 215 ICSRs and 1,562 drug-event combinations (DECs) from FAERS (Q1-Q2 2025). Agreement was measured using percentage agreement and Cohen's kappa. Results: Question-level agreement was 96.8% for Naranjo Q2 (kappa = 0.491; 95% CI 0.265-0.663), 85.4% for Q5 (kappa = 0.269; 95% CI 0.180-0.340), and 96.8% for Q10 (kappa = 0.922; 95% CI 0.885-0.951). Final causality classification agreement was 79.4% (95% CI 71.8-85.3; kappa = 0.587, 95% CI 0.450-0.690). In a retrospective subset of 60 DECs, agreement was higher for RAG-labelled than non-RAG scores for Q5 (83.3% vs 65.0%) and Q10 (100.0% vs 18.3%). Discussion: MARCA-assisted assessment showed substantial variation in agreement across Naranjo questions, with lower concordance for alternative causes. Retrospective RAG comparisons are exploratory and do not establish prospective effectiveness.

Closest papers

Nearest neighbours by meaning across the whole index.

VITAL: A Framework for Validating Agentic AI in Pharmaceutical Drug Development and Clinical Trial Operations

cs.AI ·2026-11-17 ·Sandeep Burugupalli, Pedro Matos-Filipe, Andrea Hita Ardiaca, Adam Taylor, Alex Grigorenko +8 more
similarity 0.62
Abstract

Current assurance approaches do not establish whether evidence is sufficient to validate, monitor and govern agentic artificial intelligence (AI) within a pharmaceutical context of use. Plausible outputs may conceal failures in retrieval, reasoning, orchestration or human-control points, where reference standards are unavailable. We developed and operationalised VITAL (Validation by Intended use, Traceability, Autonomy and Lifecycle evidence), a validation framework for agents in clinical development, through landscape analysis, regulatory and standards mapping, expert interviews and multi-stakeholder refinement. VITAL integrates context of use, controls, behavioural validation and lifecycle evidence within a risk-adjusted framework. We applied VITAL across epidemiology and treatment-landscape analysis, site selection, enrolment rescue and trial-design trade-off support to translate autonomy, reversibility, transparency and patient impact into proportionate validation activities, evidence requirements and auditable reconstruction of system behaviour. VITAL may inform evidence requirements and lifecycle accountability for higher-risk pharmaceutical uses; evaluation should assess reproducibility across assessors, organisations and system configurations.

0.29

TCMClinicalReason-Bench: Can Language Models Reason from Pathogenesis to Prescription over Real-World Clinical Cases?

cs.AI ·2026-10-03 ·Jirui Dai, Chenkai Zhang, Yan Jia, Yukai Wang, Ruiyang He +2 more
similarity 0.61
Abstract

Large language models (LLMs) can generate clinical narratives that are insufficiently grounded in patient-specific evidence. In traditional Chinese medicine (TCM), errors can propagate from etiology and pathogenesis through syndrome diagnosis and treatment principles to prescription generation. We developed TCMClinicalReason-Bench using 2,000 multicenter electronic health record cases to distinguish case-grounded responses from fluent but unsupported diagnostic and therapeutic conclusions. Five general-purpose and two TCM-specific LLMs were evaluated in zero-shot settings. An evidence-constrained rubric assessed seven diagnostic and therapeutic components and three cross-block relations, allowing case-supported alternatives. Qwen3.7-Plus with TCM retrieval served as the automated judge, alongside parallel blinded ratings by five senior TCM clinicians on a 600-case subset. Structural completeness was nearly saturated (99.3-100.0%), but normalized content scores ranged from 40.7% to 54.1%. The five general-purpose models averaged 50.0%, versus 41.3% for the two smaller TCM-specific models. Cross-block logic consistency ranged from 60.8% to 66.8% and correlated moderately with content across cases (Pearson's r = 0.515-0.656). Deficits were greatest in prescription generation, prescription analysis, and symptom-guided modification. In judge stress testing on 100 independent cases, perturbation detection rates across the three relations were 57%, 56%, and 31%, with contradictions detected more reliably than omissions. Separating component quality from cross-block consistency localizes failures missed by endpoint and completeness metrics and identifies where clinician oversight remains necessary.

0.18

AI Morbidity and Mortality: A Framework for Clinical AI Failure Review

cs.AI cs.HC ·2026-08-31 ·Paulius Mui, Dean F. Sittig, Steve Labkoff, Sanjay Basu
similarity 0.61
Abstract

Clinical artificial intelligence is increasingly embedded in real-world care, yet existing safety mechanisms are poorly suited to reconstructing and learning from individual AI-related errors and near-misses. Aggregate model monitoring can identify performance changes, and traditional patient safety reporting can capture adverse events, but neither is designed to explain how risk emerges across the interaction among AI systems, clinicians, workflows, and institutional controls. We propose AI Morbidity and Mortality (AI M&M), a structured, blameless framework for case-based review of clinical AI failures. The framework combines standardized case intake, evidence preservation and investigator-level reconstruction, tool-in-loop attribution, and corrective-action tracking. Each event is classified across four linked dimensions: Trigger - Mechanism - Clinical Pathway - Corrective Action, separating the condition that exposed a vulnerability from the process that produced risk, its consequence for care, and the remediation assigned. We demonstrate the framework using five illustrative outpatient medication and clinical decision-support cases; two clinician reviewers independently applied all four classification axes and reached agreement across all 20 axis-level classifications. AI M&M is intended to complement, rather than replace, model monitoring, patient safety reporting, and regulatory oversight by converting individual AI-in-workflow failures into actionable institutional learning. Prospective evaluation across institutions, AI systems, and clinical settings is needed.

0.13

RECITE: Revising Eligibility Criteria Incorporating Textual Evidence

cs.AI ·2026-10-30 ·Russell Ro, Reza Abbasi-Asl
top venuebenchmark similarity 0.61
Abstract · 18 pages, 4 figures, 4 tables. Extended version of a paper in KDD 2026 (32nd ACM SIGKDD Conference on Knowledge Discovery and Data Mining). …

Overly restrictive eligibility criteria contribute to widespread enrollment failure in clinical trials, yet published recommendations for how specific criteria should be broadened remain disconnected from trial design at scale. We introduce RECITE (Revising Eligibility Criteria Incorporating Textual Evidence), a framework for automated discovery, extraction, and implementation of evidence-based eligibility criteria revisions. RECITE uses protocol amendment documents from ClinicalTrials.gov to construct a dataset of 11,913 curated instances across 5,735 trials, each pairing original criteria with documentary evidence and target revisions. We benchmark fifteen LLM configurations under truncated-to-context-window and retrieval-augmented generation conditions, on a 3,116-instance sample under an LLM-as-judge protocol validated against ten domain experts (judge vs. human quadratic-weighted Cohen's $κ_{qw} = 0.694 \pm 0.096$). The best open-weight model, Gemma 2 9B, achieves $κ_{qw}$-aligned ordinal score $3.0 \pm 0.9$ on a 0--4 scale (normalized 0.742) and the best closed-weight model, GPT-4o, reaches $3.0 \pm 0.8$ (normalized 0.745). Using an agentic literature discovery system, we then identified 44 paper--trial matches across five publications providing trial-design and EC-modification evidence. Our findings suggest that existing clinical knowledge can be operationalized into actionable trial design recommendations.

0.55

DrugTargetWorld: A Synthetic Biobank for Training and Benchmarking AI Scientists

cs.AI ·2026-10-07 ·Samuel Margolis, Paul Schmiedmayer, Alan Huang, Ethan Chen, Ishan Bhattacharjee +10 more
code/data similarity 0.61
Abstract · 34 pages main text, 92 pages supplementary material; 6 main figures. Project: https://DrugTargetWorld.vercel.app. Code: https://github.com/s…

Drug target discovery requires distinguishing molecules that causally drive disease from those that are merely associated with it. Training and evaluating AI agents to perform this workflow end-to-end is difficult because real world biobanks lack known causal ground truth and participant-level data is access controlled. We introduce DrugTargetWorld, a framework that procedurally generates simulated biobanks, or "worlds," with known but concealed causal structure. Each world contains genotypes, proteins, health records, outcomes, and synthetic magnetic resonance imaging (MRI) for 54,000 participants. Agents must construct a disease phenotype, identify causal driver proteins, infer the beneficial direction of modulation, and optionally conduct virtual 'wet lab' experiments. We evaluated nine agents in 540 episodes across 20 cardiovascular worlds and three experimental budgets. Opus 5 and GPT-5.6 Sol achieved the highest mean composite scores, 39.98 and 35.38 of 100, respectively, and both recovered 64% of causal drivers on average. However, no agent reliably distinguished misleading non-causal proteins, and performance remained limited by the integrative judgments required to connect phenotype construction, causal evidence, and intervention decisions. By making each world's causal structure known to the evaluator but hidden from the agent, DrugTargetWorld turns end-to-end drug target discovery into a scalable training and evaluation problem with verifiable reward.

0.41

CLEAR: Cross-Source Evidence Adjudication for Large Language Models in Medicine

cs.AI cs.CL ·2026-09-14 ·Shuai Wang, Yize Zhao, Qingyu Chen
similarity 0.60
Abstract · 31 pages

Medical knowledge evolves continuously, whereas the parametric knowledge encoded in large language models (LLMs) is fixed at training time. External retrieval, including retrieval-augmented generation (RAG), can provide access to newly available evidence, but retrieved information may be irrelevant, incomplete, or conflicting. As a result, external retrieval can in turn degrade the factual accuracy and evidence grounding of LLM outputs. To address this challenge, we propose \textbf{CLEAR}, an agentic framework for cross-source evidence adjudication in LLMs in medicine. CLEAR independently generates candidate answers from three complementary pathways---parametric knowledge, locally curated corpora, and dynamically retrieved evidence---reflecting three common sources of information available to LLMs. An aggregation verifier jointly evaluates the candidates, supporting evidence, provenance, and source-quality information to identify agreement and conflict across sources. An adjudication module then determines whether the current conclusion should be preserved or revised through complementary override-guard and challenge-audit mechanisms, while unresolved conflicts trigger targeted follow-up search and re-adjudication.

0.11

TrialAtlas: Multi-Agent Research Organization for Clinical Trial Design and Optimization

cs.CL ·2026-09-18 ·Jiacheng Lin, Zifeng Wang, Zheng Chen, Erick Scott, Ziwei Yang +3 more
similarity 0.60
Abstract

Nearly 90% of drugs entering clinical development ultimately fail, despite billions of dollars in investment. Pharmaceutical companies therefore rely on clinical development planning (CDP) and probability of technical and regulatory success assessment to anticipate development risks, yet these decisions remain labor-intensive and subjective, requiring experts across clinical science, statistics, regulatory affairs, and competitive intelligence to jointly acquire, synthesize, and reason over heterogeneous evidence. Here, we introduce TrialAtlas, a memory-augmented multi-agent research organization for CDP that mirrors this collaborative process by coordinating specialized agents for literature synthesis, competitive trial intelligence, regulatory precedent analysis, and integrated reasoning over trial design and development risk. TrialAtlas further learns from historical clinical trials and regulatory outcomes, including prior New Drug Applications (NDAs), to ground its decisions in accumulated development experience. To evaluate these capabilities in an authentic regulatory setting, we introduce TrialAtlasBench, constructed from 291 FDA Complete Response Letters and spanning three practical tasks: detecting trial design deficiencies, recommending actionable design improvements, and predicting technical and regulatory success. TrialAtlas achieves an F1 score of 50.0% for deficiency detection, outperforming the strongest baseline by 6.1 points, and reaches 85.3% balanced accuracy and 84.7% F1 for prediction of technical and regulatory success, improving over the best baselines by 6.7 points in balanced accuracy and 12.0 points in Cohen's kappa. In expert evaluation, 86.4% of TrialAtlas-generated concerns were judged valid, compared with 83.1% for OpenAI DeepResearch and 59.3% for Gemini DeepResearch.

0.40

EGIP: An Evidence-Grounded Interaction Protocol for Clinical Agents

cs.CL ·2026-10-17 ·Zecheng Ren, Ruichen Cong, Yi Min Chen, Jing Zhang, Feiyang Chen +6 more
similarity 0.60
Abstract

Interactive clinical agents acquire evidence through patient dialogue and diagnostic examinations, yet their performance also depends on how the interaction environment exposes information, available actions, and examination results. When these conditions are implicit or inconsistently controlled, final-answer accuracy can conflate diagnostic reasoning with the effects of the interaction protocol. We propose the \textbf{E}vidence-\textbf{G}rounded \textbf{I}nteraction \textbf{P}rotocol (EGIP), which enforces role-specific information boundaries, exposes diagnostic actions without revealing their results, retrieves examination results from stored clinical records, and organizes acquired evidence for final decision-making. By separating evidence acquisition from terminal prediction, EGIP enables different decision strategies to operate on the same observations. We evaluate EGIP across two clinical-agent frameworks, five datasets, and six language models. EGIP improves diagnostic accuracy over native baselines across all primary comparisons. A clinician review further shows that the proportion of automatically scored correct responses jointly judged evidence-supported rises from 10.20\% to 36.55\%. These findings support the effectiveness of EGIP as a unified interaction protocol for improving clinical-agent performance through controlled evidence access and acquisition.

0.23